Latest News

Post hoc analyses from the phase 3 GRADUATE program suggest higher baseline tau pathology may limit amyloid removal with gantenerumab, offering new insight into factors that could influence response to anti-amyloid therapy.

Leslie M. Thompson, PhD; Ravi Rajmohan, MD, and Jefferson W. Chen, MD, from UCI Health discuss the rationale, delivery, and early steps of REGEN4HD, the world's first neural stem cell phase 1b/2a clinical trial for Huntington disease.

In a prespecified analysis presented at AAIC 2026, findings showed that plasma p-tau217 declined from baseline in valiltramiprosate-treated MCI patients compared with placebo over 78 weeks.

Here's some of what is coming soon to NeurologyLive® this week.

In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics

An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, whereas past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Carol Rosen, MD, professor emerita of pediatrics at Case Western Reserve University School of Medicine, discussed the transformation of pediatric sleep medicine from a clinical curiosity to a core medical specialty at SLEEP 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]

The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.

AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.